Cargando…

Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus

INTRODUCTION: The safety and efficacy of pembrolizumab administration in patients with urothelial carcinoma and underlying autoimmune disease (including overlap syndrome) is unknown. CASE PRESENTATION: We present the case of a 67‐year‐old woman with cT3N2M0 metastatic renal pelvic cancer who had bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurokawa, Masayuki, Naito, Sei, Ito, Suguru, Takai, Satoshi, Kawamura, Yuko, Kaneko, Hisashi, Kakizaki, Hiroshi, Tsuchiya, Norihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469821/
https://www.ncbi.nlm.nih.gov/pubmed/32914068
http://dx.doi.org/10.1002/iju5.12175
_version_ 1783578472610791424
author Kurokawa, Masayuki
Naito, Sei
Ito, Suguru
Takai, Satoshi
Kawamura, Yuko
Kaneko, Hisashi
Kakizaki, Hiroshi
Tsuchiya, Norihiko
author_facet Kurokawa, Masayuki
Naito, Sei
Ito, Suguru
Takai, Satoshi
Kawamura, Yuko
Kaneko, Hisashi
Kakizaki, Hiroshi
Tsuchiya, Norihiko
author_sort Kurokawa, Masayuki
collection PubMed
description INTRODUCTION: The safety and efficacy of pembrolizumab administration in patients with urothelial carcinoma and underlying autoimmune disease (including overlap syndrome) is unknown. CASE PRESENTATION: We present the case of a 67‐year‐old woman with cT3N2M0 metastatic renal pelvic cancer who had been treated with prednisolone for overlap syndrome involving systemic sclerosis and systemic lupus erythematosus for 20 years. She had a remarkable response to pembrolizumab as a third‐line systemic therapy, wherein the tumor reduced in size and all regional lymph node and pulmonary metastases disappeared. She did not develop any immune‐related adverse events or autoimmune disease flare‐ups during the treatment. CONCLUSION: This case report suggests that pembrolizumab could be beneficial to patients with urothelial carcinoma and underlying well‐controlled overlap syndrome.
format Online
Article
Text
id pubmed-7469821
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74698212020-09-09 Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus Kurokawa, Masayuki Naito, Sei Ito, Suguru Takai, Satoshi Kawamura, Yuko Kaneko, Hisashi Kakizaki, Hiroshi Tsuchiya, Norihiko IJU Case Rep Case Report INTRODUCTION: The safety and efficacy of pembrolizumab administration in patients with urothelial carcinoma and underlying autoimmune disease (including overlap syndrome) is unknown. CASE PRESENTATION: We present the case of a 67‐year‐old woman with cT3N2M0 metastatic renal pelvic cancer who had been treated with prednisolone for overlap syndrome involving systemic sclerosis and systemic lupus erythematosus for 20 years. She had a remarkable response to pembrolizumab as a third‐line systemic therapy, wherein the tumor reduced in size and all regional lymph node and pulmonary metastases disappeared. She did not develop any immune‐related adverse events or autoimmune disease flare‐ups during the treatment. CONCLUSION: This case report suggests that pembrolizumab could be beneficial to patients with urothelial carcinoma and underlying well‐controlled overlap syndrome. John Wiley and Sons Inc. 2020-06-16 /pmc/articles/PMC7469821/ /pubmed/32914068 http://dx.doi.org/10.1002/iju5.12175 Text en © 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kurokawa, Masayuki
Naito, Sei
Ito, Suguru
Takai, Satoshi
Kawamura, Yuko
Kaneko, Hisashi
Kakizaki, Hiroshi
Tsuchiya, Norihiko
Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus
title Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus
title_full Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus
title_fullStr Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus
title_full_unstemmed Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus
title_short Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus
title_sort successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469821/
https://www.ncbi.nlm.nih.gov/pubmed/32914068
http://dx.doi.org/10.1002/iju5.12175
work_keys_str_mv AT kurokawamasayuki successfulpembrolizumabtreatmentinapatientwithmetastaticurothelialcarcinomaandunderlyingoverlapsyndromeinvolvingsystemicsclerosisandsystemiclupuserythematosus
AT naitosei successfulpembrolizumabtreatmentinapatientwithmetastaticurothelialcarcinomaandunderlyingoverlapsyndromeinvolvingsystemicsclerosisandsystemiclupuserythematosus
AT itosuguru successfulpembrolizumabtreatmentinapatientwithmetastaticurothelialcarcinomaandunderlyingoverlapsyndromeinvolvingsystemicsclerosisandsystemiclupuserythematosus
AT takaisatoshi successfulpembrolizumabtreatmentinapatientwithmetastaticurothelialcarcinomaandunderlyingoverlapsyndromeinvolvingsystemicsclerosisandsystemiclupuserythematosus
AT kawamurayuko successfulpembrolizumabtreatmentinapatientwithmetastaticurothelialcarcinomaandunderlyingoverlapsyndromeinvolvingsystemicsclerosisandsystemiclupuserythematosus
AT kanekohisashi successfulpembrolizumabtreatmentinapatientwithmetastaticurothelialcarcinomaandunderlyingoverlapsyndromeinvolvingsystemicsclerosisandsystemiclupuserythematosus
AT kakizakihiroshi successfulpembrolizumabtreatmentinapatientwithmetastaticurothelialcarcinomaandunderlyingoverlapsyndromeinvolvingsystemicsclerosisandsystemiclupuserythematosus
AT tsuchiyanorihiko successfulpembrolizumabtreatmentinapatientwithmetastaticurothelialcarcinomaandunderlyingoverlapsyndromeinvolvingsystemicsclerosisandsystemiclupuserythematosus